FDA warned Clinical Formula LLC that its Clinical Formula Bleaching Lotion is an unapproved and misbranded skin-lightening drug.
What happened
FDA reviewed the product label for Clinical Formula™ Bleaching Lotion and cited claims that it bleaches hyperpigmented skin and contains hydroquinone 2%. FDA said this skin bleaching drug is not generally recognized as safe and effective under an applicable proposed rule, so it is deemed a new drug needing an approved application; no FDA-approved application is in effect.
What FDA found
The company marketed a skin bleaching drug without an FDA-approved new drug application.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The product is misbranded because it is a nonprescription drug that does not meet section 505G requirements and has no approved application.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)The product label claims the lotion bleaches hyperpigmented skin, showing it is intended for use as a drug.
section 201(g)(1)(B)/(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B)/(C); 21 CFR 201.128
What FDA wants
FDA asks the company to respond in writing within 15 working days, saying what it has done to correct the violations and prevent recurrence, or giving reasons for delay and a completion schedule.
Who should pay attention
- companies selling OTC skin-lightening products
- brands using hydroquinone in cosmetic or drug products
- retailers and distributors of skin-lightening lotions
This is a summary. Read the original letter on fda.gov.